Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

The Shoddy Results That Have These Four Stocks Plunging Today

Page 1 of 2

The shareholders of CIT Group Inc. (NYSE:CIT), AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), Avis Budget Group Inc. (NASDAQ:CAR), and Louisiana-Pacific Corporation (NYSE:LPX) can’t be overly pleased with the performance of their investments today, as the value of their stocks are plunging for various reasons. Let’s take a closer look at the downside catalysts and analyze what hedge funds think of them long-term.

Wall Street Stocks Market Insider Trading

Rawpixel /

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 53 percentage points since the end of August 2012. These stocks returned a cumulative of 102% vs. a 48.7% gain for the S&P 500 Index (see the details here). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

CIT Group Inc. (NYSE:CIT) is off by 2.78% in afternoon trading after reporting third quarter earnings of $0.80 per share on revenues of $520.9 million this morning, the latter up by 33.8% year-over-year. The dip comes despite the base results beating estimates by a solid $0.09 per share in earnings and  $0.54 million in revenues. The company’s financing and leasing assets in the North America Banking and Transportation & International Finance division grew by 3% quarter-over-quarter, while management returned nearly $170 million of capital back to shareholders during the quarter. The company also closed the OneWest Bank acquisition, which added $20 billion in assets and $14 billion in deposits. Tier 1 common ratio was 12.4%. Despite the selloff, this wasn’t a bad quarter. If management can realize better-than-expected value from strategic alternatives over its $10 billion Commercial Air business, look for shares to rally. Of the 730 elite funds that we track, 33 of them owned $1.09 billion of CIT Group Inc. (NYSE:CIT)’s shares, representing 13.50% of the float, on June 30. Keith Meister’s Corvex Capital owned 1.52 million CIT shares at the end of June.

Follow Cit Group Inc (NYSE:CIT)
Trade (NYSE:CIT) Now!

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares are down by 18.85% after reporting third quarter earnings of $1.02 per share on revenues of $103.47 million, up by 339.9% year-over-year, though the results nonetheless missed estimates by $0.19 per share and $10.41 million, respectively. Guidance was also a bit soft, with management expecting non-GAAP net income of $165 million-to-$180 million on revenues of $425 million-to-$450 million, versus the previous guidance of $180 million-to-$195 million in income on revenues of $395 million-to-$430 million. Makena’s net sales were $65.2 million in the quarter, up by 36% year-over-year, although future growth for the company’s number one product may be harder to come by given the increased regulatory attention on drug prices. Hedge funds we follow were bullish on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the second quarter, with 29 of them owning 29.80% of the company’s common stock at the end of June, valued at $628.06 million.

Follow Amag Pharmaceuticals Inc. (NASDAQ:AMAG)
Trade (NASDAQ:AMAG) Now!

On the next page, we examine why Avis Budget and Louisiana-Pacific Corporation are lower in afternoon trading. 

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!